Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
14.22
+0.74 (5.49%)
At close: Oct 8, 2025, 4:00 PM EDT
14.11
-0.11 (-0.77%)
After-hours: Oct 8, 2025, 5:51 PM EDT
Avalo Therapeutics Revenue
Avalo Therapeutics had revenue of $441.00K in the twelve months ending June 30, 2025, down -45.35% year-over-year. In the year 2024, Avalo Therapeutics had annual revenue of $441.00K, down -77.08%.
Revenue (ttm)
$441.00K
Revenue Growth
-45.35%
P/S Ratio
299.54
Revenue / Employee
$19,174
Employees
23
Market Cap
187.03M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 441.00K | -1.48M | -77.08% |
Dec 31, 2023 | 1.92M | -16.13M | -89.34% |
Dec 31, 2022 | 18.05M | 12.65M | 234.40% |
Dec 31, 2021 | 5.40M | -1.30M | -19.42% |
Dec 31, 2020 | 6.70M | -51.35K | -0.76% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
AVTX News
- 7 days ago - Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources - GlobeNewsWire
- 16 days ago - Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors - GlobeNewsWire
- 6 weeks ago - Avalo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Avalo Therapeutics: Speculative Buy Ahead Of AVTX-009's LOTUS Results - Seeking Alpha
- 2 months ago - Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates - GlobeNewsWire
- 4 months ago - Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors - GlobeNewsWire
- 5 months ago - Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates - GlobeNewsWire
- 5 months ago - Avalo Therapeutics to Participate in The Citizens Life Sciences Conference - GlobeNewsWire